35 results about "Mite allergen" patented technology

The invention provides a method for producing a modified major mite allergen, obtained by altering a major allergen of house dust mites by gene engineering, which involve the steps of culturing prokaryotic or eukaryotic host cells transformed with a replication vector containing a gene encoding modified major mite allergen expressed from a promoter and collecting the expressed modified major mite allergen from the culture. The present invention provides a modified major mite allergen produced by the method, DNA molecules encoding same, and a pharmaceutical composition containing the modified major mite allergen.

The invention discloses a method for detecting mite allergen specific antibody in blood serum. The method comprises the following steps of: coupling mite allergen with surface carboxyl modified magnetic microspheres to prepare immunomagnetic microspheres; and mixing and incubating the blood serum to be detected and the immunomagnetic microspheres in holes of an elisa (enzyme-linked immunosorbent assay) plate to combine mite allergen with mite allergen specificity IgE in the blood serum, and detecting by adopting an enzyme-linked immunosorbent method after the elisa plate is washed. In the method disclosed by the invention, a mite allergen is directly coupled onto the surfaces of magnetic microspheres, thus all the impurities except the mite allergen specific antibody in the blood serum can be conveniently removed; and targeted mite allergen specificity antibody detection is carried out, detection time is shortened, and sensitivity, specificity and accuracy of detection are improved. The mite allergen immunomagnetic microspheres prepared by the invention can be used in standard automatic detection to improve detection efficiency.

The invention provides a method for preparing an allergen diagnostic reagent of acute allergic diseases caused by dermatophagoides pteronyssinus (Der p for short). The allergen diagnostic reagent is Der p allergen pricking liquid. The invention also provides a method for preparing an allergen diagnostic reagent raw material, namely Der p pure mite allergen, a method for evaluating the valence of the allergen diagnostic reagent and a purpose for specifically diagnosing the allergic diseases. The allergen diagnostic reagent achieves the aim for detecting whether a patient is allergic to a matter to cause a disease by a sensitized principle. The Der p pure mite allergen raw material has short culture period and high purity, and the pricking liquid made of the raw material has high activity, thereby greatly reducing a skin test risk of the allergic patient and improving the safety of clinical medical treatment.

The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from D. pteronyssinus useful for the prevention and treatment of allergies, particularly allergies caused by mites. Specifically, the invention describes hybrid proteins composed of fragments of allergens Derp p l y Derp p 2 with hypoallergenic characteristics and maintain their immunogenic capacity, being particularly useful for the treatment of allergy. The invention also describes the production methods of these polypeptides in heterologous expression systems. Besides, the invention describes efficient purification methods of these hybrid proteins.

The invention provides a monoclonal antibody capable of recognizing an allergen of DerP2, wherein the monoclonal antibody is secreted by a hybridoma cell strain DerP2 with the accession number being CCTCC NO:C2014112. The invention further provides an ELISA kit for quantitative detection of dermatophagoides pteronyssinus allergens of DerP2 and Derf2. The ELISA kit includes an enzyme label plate, a specimen diluent, a coating antibody, a detecting antibody, a detecting antibody diluents, a standard substance, a washing liquid, a substrate chromogenic reagent, and a stopping solution, wherein the coating antibody is the monoclonal antibody related in the claim 1, and the detecting antibody is an anti-DerP2 polyclonal antibody marked with HRP. The anti-DerP2 monoclonal antibody is excellent in specificity and produces no cross reaction with a DerP1 protein. Therefore, based on the anti-DerP2 monoclonal antibody, the fast, specific, and sensitive in-vitro diagnostic kit for detecting the allergens is established.

A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.

The invention provides an intelligent mite cultivating and collecting device, which comprises a box body with a sealed holding space and a feeding device 2, a collecting device, a lighting device 4, atemperature control device 5 and a humidity control device 6 which are arranged in the sealed holding space. The invention further provides a method for standardly cultivating the mite by using the device. The method is time-saving and labor-saving, able to realize the scaled and standardized mite cultivation, and good for pushing the development and study of the mite allergen and vaccine.

The invention discloses a moisture-proof mite allergen soluble microneedle. The moisture-proof mite allergen soluble microneedle comprises a needle body and a backing, wherein the needle body comprises mite allergen and a composite matrix material, the composite matrix material is a mixture of a methyl vinyl ether-maleic anhydride copolymer and polyvinyl alcohol, and the content ratio of the methyl vinyl ether-maleic anhydride copolymer to the polyvinyl alcohol is (1:1.5)-(2:1). According to the moisture-proof mite allergen soluble microneedle, by screening the appropriate matrix material type and content (Gantrez S-97+PVA) and the appropriate drug loading ratio, the prepared mite allergen soluble microneedle can still have good mechanical strength under a high-humidity condition, is easy to pierce into the skin for drug administration, and does not affect the activity of the mite allergen.

The invention discloses a sublingual temperature-sensitive gel containing mite allergen. The sublingual temperature-sensitive gel is composed of mite allergen, a cationic monomer and a temperature-sensitive gel material, wherein the content ratio of the cationic monomer to the temperature-sensitive gel material is (1:2)-(1:1). According to the sublingual temperature-sensitive gel containing mite allergen, the sublingual temperature-sensitive gel is provided on the basis of a common sublingual drop containing mite allergen, the advantage of convenience in administration of the sublingual drop is maintained, the retention time of a vaccine under the tongue is prolonged, and the drug effect is improved; the gelling time of the temperature-sensitive gel is shortened, the loss caused by swallowing in the administration process is reduced, and the dosage is reduced; and the thermo-sensitivity of the temperature-sensitive gel to adsorb protein is overcome, the adsorption of the gel to the protein in a liquid state is improved, and then the dosage is reduced.

The invention discloses an adjuvant-containing mite allergen soluble microneedle patch. The adjuvant-containing mite allergen soluble microneedle patch comprises a needle body and a backing, wherein the needle body comprises a mite allergen, a composite adjuvant and a matrix material; the composite adjuvant is a mixture of microcrystalline tyrosine and alfalfa polysaccharide; and the content ratio of the microcrystalline tyrosine to the alfalfa polysaccharide is (2:1)-(1:2). According to the mite allergen soluble microneedle patch provided by the invention, by selecting the appropriate type and content of the composite adjuvant and the mass ratio of the matrix material in the needle body, the prepared mite allergen soluble microneedle patch is appropriate in mechanical strength, good in treatment effect and excellent in safety.

A method for purifying a modified major mite allergen obtained by the genetic recombination technique and a purified modified major mite allergen obtained by said method for purification are provided. A method for purifying a modified major mite allergen obtained by the genetic recombination technique, which comprises the purification steps: (1) Washing and recovering inclusion bodies containing a modified major mite allergen obtained by the genetic recombination technique with MF membrane; (2) Dissolving said inclusion bodies followed by refolding; (3) Concentrating a solution containing the modified major mite allergen with simultaneous removal of low molecular weight components with ultrafiltration membrane; (4) Recovering the modified major mite allergen in non-adsorbed fractions with an anion exchanger; (5) Recovering the modified major mite allergen in adsorbed fractions with a hydrophobic gel; and (6) Recovering the modified major mite allergen in adsorbed fractions with an anion exchanger, and a modified major mite allergen with high purity obtained by said method for purification.

The invention relates to a mite allergen specific yolk immunoglobulin antibody and an anti-allergic preparation thereof. The mite allergen specific yolk immunoglobulin antibody is mainly prepared by the following method: extracting a mite allergen, carrying out supplementary immunization on chickens, preparing crude extract, finely extracting and purifying. The mite allergen specific yolk immunoglobulin antibody and the preparation thereof, provided by the invention, have the advantages of high antibody activity and specific defending effect on local sensitization caused by mites, and have a good rejection effect on the local sensitization caused by sensibiligen; the mite allergen specific yolk immunoglobulin antibody has no immunogenicity, no adverse effect on skin mucous membranes of human bodies and high safety performance.

The invention discloses a slow-release soluble microneedle delivery system for mite-allergen-loaded microspheres. The system comprises a needle body and a backing, wherein the needle body comprises the mite allergen microspheres and a matrix material, the matrix material is a mixture of a methyl vinyl ether-maleic anhydride copolymer and polyethylene glycol, and the content ratio of the methyl vinyl ether-maleic anhydride copolymer to the polyethylene glycol is (2:1)-(1:1). According to the system, the specific component types and content ratio of the mite allergen microspheres are selected, so that the prepared mite allergen slow-release microspheres are excellent in performance and can well load mite allergen; and the specific component types and content ratio of the matrix material and the specific drug loading ratio are selected, so that the prepared mite allergen slow-release soluble microneedle is excellent in formability, mechanical strength and other performance, the release time of the drug is greatly prolonged, the treatment effect is superior to that of a non-slow-release mite allergen soluble microneedle, the administration frequency of the mite allergen can be reduced, and the compliance of a patient can be improved.

The invention provides a dust mite allergen quick-disintegrating sublingual tablet vaccine and a preparation method thereof. The vaccine is a quick-disintegrating sublingual tablet of dust mite allergens prepared by direct freeze-drying method, and contains dust mite allergens and corresponding excipients, flavoring agent, pigments, etc. in which the dust mite allergens are Dermatophagoides pteronyssinus allergens or Dermatophagoides farinae allergens or mixed dust mite allergens of both. The sublingual tablet vaccine has the advantages of stable biological activity, long effect period, easy storage, convenient use, disintegration, quick release of active ingredients and the like compared with the traditional allergen sublingual drop vaccine and can provide more convenient and reliable specific desensitization treatment means for patients allergic to dust mites.

The present invention relates to a polypeptide derived from a mite allergen (Der p 2) useful for the prophylactic treatment of allergic asthma.